Im­mune Reg­u­la­tion makes Pe­ter Green­leaf chair­man and as­sem­bles a quin­tet of new ex­ecs; Bob Cough­lin moves on from Mass­Bio to JLL

Pe­ter Green­leaf

→ In Sep­tem­ber, Im­mune Reg­u­la­tion raked in $53.4 mil­lion in a Se­ries B for two pro­grams in rheuma­toid arthri­tis and asth­ma. This week, the British biotech has named Au­rinia CEO Pe­ter Green­leaf chair­man of the board while an­nounc­ing five ap­pointees that have joined CEO Jonathan Rig­by’s crew. Green­leaf took the reins at Au­rinia — which just yes­ter­day struck up an agree­ment with Ot­su­ka to com­mer­cial­ize vo­closporin in Japan and Eu­rope — in April 2019. He was al­so the CEO of Cere­cor and Su­cam­po Phar­ma­ceu­ti­cals.

Im­mune Reg­u­la­tion’s new CBO, Woody Bryan, was pre­vi­ous­ly the SVP of busi­ness de­vel­op­ment at Uro­Gen and he was with Green­leaf in the same BD ca­pac­i­ty at Su­cam­po when Mallinck­rodt bought it out in late 2017 for $1.2 bil­lion. New­ly-mint­ed COO Per­ry Calias was Cere­cor’s CSO and head of R&D, and he was al­so with Su­cam­po/Mallinck­rodt serv­ing as VP of glob­al CMC and prod­uct de­vel­op­ment. And CMO Jeff My­ers hails from Por­to­la Phar­ma­ceu­ti­cals, where he was SVP of glob­al med­ical af­fairs and in­ter­im CMO.

Round­ing out the band of new ex­ecs, Nan­cy Vinh (VP, clin­i­cal op­er­a­tions) is an­oth­er Por­to­la alum who led their clin­i­cal op­er­a­tions, while pre­vi­ous stops for Mary­lyn Rig­by (VP of mar­ket­ing and in­vestor re­la­tions) in­clude Unit­ed Ther­a­peu­tics and SteadyMed Ther­a­peu­tics.

Robert Cough­lin

Robert Cough­lin has quick­ly found a new land­ing spot af­ter leav­ing Mass­Bio as their CEO: He’s now man­ag­ing di­rec­tor for JLL’s life sci­ence in­dus­try. It’s their sec­ond ma­jor hire in the life sci­ences prac­tice in three months as Travis Mc­Cready took on the role of JLL’s ex­ec­u­tive di­rec­tor and na­tion­al prac­tice leader in Sep­tem­ber.

Cough­lin spent 13 years at Mass­Bio in a pe­ri­od of sub­stan­tial growth. His in­ter­im suc­ces­sor is Kendalle Burlin O’Con­nell, who is Mass­Bio’s COO.

→ There’s a new sher­iff in town at Liq­uidia just weeks af­ter the FDA gave them a lump of coal in the form of a CRL for their lead pul­monary ar­te­r­i­al hy­per­ten­sion drug LIQ861. Dami­an de­Goa takes over as CEO fol­low­ing the re­tire­ment of Neal Fowler af­ter 2 years as CEO of RareGen, which Liq­uidia snapped up this year. Dur­ing his tenure, RareGen col­lab­o­rat­ed with San­doz in com­mer­cial­iza­tion ef­forts for tre­pros­tinil, a Re­mod­ulin gener­ic for pul­monary ar­te­r­i­al hy­per­ten­sion (PAH).

Louise Rodi­no-Kla­pac

Sarep­ta is do­ing some se­ri­ous lead­er­ship re­tool­ing while their saga con­tin­ues with the FDA over the biotech’s Duchenne mus­cu­lar dy­s­tro­phy gene ther­a­py. All the moves come from with­in: Ian Es­tepan slides in­to the CFO post af­ter serv­ing as SVP, chief of staff and cor­po­rate af­fairs; for­mer SVP of gene ther­a­py Louise Rodi­no-Kla­pac is the new CSO; Dal­lan Mur­phy rips off the in­ter­im tag and is now the per­ma­nent chief com­mer­cial of­fi­cer; and Ryan Brown, who joined Sarep­ta 2 years ago, re­places the re­tir­ing Ty How­ton as in­ter­im gen­er­al coun­sel. End­points’ Ja­son Mast has more on the ap­point­ments from ear­li­er this week.

→ Af­ter say­ing good­bye to Al­ny­lam this sum­mer, Bar­ry Greene has tak­en on a new chal­lenge as CEO of Sage Ther­a­peu­tics. And what a chal­lenge it will be: Sage put 340 em­ploy­ees on the chop­ping block in April, which amount­ed to more than half of the biotech’s work­force, with the deep cuts com­ing short­ly af­ter a Phase III fail for their ex­per­i­men­tal de­pres­sion drug Sage-217. Greene, who logged 17 years at John Maraganore-led Al­ny­lam, re­places Jeff Jonas, who makes the tran­si­tion to his new role of chief in­no­va­tion of­fi­cer. Greene had been a mem­ber of Sage’s board of di­rec­tors since Oc­to­ber.

Michael Var­ney

Michael Var­ney is tack­ing on a new role at Jonathan Lim-led Eras­ca by join­ing the com­pa­ny’s board of di­rec­tors. Var­ney stepped in­to the com­pa­ny in Au­gust, open­ing up a new chap­ter in his ca­reer af­ter step­ping down from a high-pro­file job as head of re­search and ear­ly de­vel­op­ment at Roche’s pres­ti­gious gRED or­ga­ni­za­tion in South San Fran­cis­co. Var­ney cur­rent­ly serves as Eras­ca’s chair­man of R&D and is al­so a part of their sci­en­tif­ic ad­vi­so­ry board. In ad­di­tion, Var­ney is a life sci­ences se­nior ad­vi­sor at Fra­zier Health­care Part­ners.

Abid Ansari

Abid Ansari has de­cid­ed to step down as CFO of Durham, NC-based Pre­ci­sion Bio­Sciences to pur­sue an­oth­er op­por­tu­ni­ty. Ansari will stick around un­til the end of the year dur­ing the tran­si­tion while Alex Kel­ly, who was just in this space a cou­ple months back when he took the chief cor­po­rate af­fairs of­fi­cer job, as­sumes the in­ter­im CFO gig in Ansari’s stead. Ansari had been with Matt Kane’s crew at Pre­ci­sion Bio­Sciences for the last 5 years. The news comes just weeks af­ter Pre­ci­sion part­nered with Eli Lil­ly on a genome edit­ing deal ap­proach­ing $2.7 bil­lion.

Toss­ing their lead pro­gram for an­ti-ag­ing in the waste­bas­ket and fol­low­ing that up with job cuts and re­struc­tur­ing, Uni­ty Biotech­nol­o­gy pres­i­dent Ned David is step­ping down Dec 31, while ear­ly in­vestor Bob Nelsen and David Lacey have ex­it­ed Uni­ty’s board of di­rec­tors. Con­cur­rent with these moves, they’re wav­ing in a new board mem­ber with Gilmore O’Neill, a Bio­gen vet who is Sarep­ta’s CMO and EVP of R&D. Our Max Gel­man has more de­tails.

Jean-Marc Bellemin

→ The folks at Io­vance have se­lect­ed Jean-Marc Bellemin as CFO. Be­fore mak­ing the switch to Io­vance — in a hold­ing pat­tern with a de­lay in their BLA fil­ing for li­fileu­cel, the Cal­i­for­nia biotech’s tu­mor-in­fil­trat­ing lym­pho­cyte (TIL) ther­a­py — Bellemin was CFO of Grit­stone On­col­o­gy for near­ly 3 years. Bellemin al­so spent more than 15 years in a num­ber of ca­pac­i­ties at Acte­lion, round­ing out his time there as SVP and CFO, head of fi­nance and mar­ket ac­cess un­til J&J grabbed hold of the com­pa­ny in 2017.

David En­loe has been named pres­i­dent and CEO of Malvern, PA-based CD­MO Re­cro, suc­ceed­ing Ger­ri Hen­wood. En­loe pre­vi­ous­ly helmed Aji­nomo­to Bio-Phar­ma Ser­vices, a CD­MO out of San Diego. Be­fore Aji Bio-Phar­ma, he led the vi­ral ther­a­peu­tics busi­ness unit at Lon­za.

Andy Kidd

Aptinyx may have a new lease on life with their pos­i­tive Phase II re­sults in post-trau­mat­ic stress dis­or­der from Oc­to­ber af­ter their di­a­bet­ic pe­riph­er­al neu­ropa­thy im­plo­sion near­ly two years ago. Now Andy Kidd has added pres­i­dent to his cur­rent COO ti­tle. Kidd start­ed out as Aptinyx’s chief com­mer­cial of­fi­cer in 2017 be­fore mov­ing to the COO post in March 2019. Pri­or to Aptinyx, he was with Bax­ter for a decade, even­tu­al­ly work­ing his way up to SVP of strat­e­gy and busi­ness de­vel­op­ment.

Ver­tex alum Sath Shuk­la has jumped on board at Spero Ther­a­peu­tics as CFO. Shuk­la makes the switch from em­bat­tled Zio­pharm On­col­o­gy — which fi­nal­ly end­ed its ac­tivist at­tack from mi­nor­i­ty in­vestor Wa­ter­Mill — where he served in the same ca­pac­i­ty. Shuk­la had a sev­en-year run at Ver­tex as their VP and glob­al head of cor­po­rate fi­nance be­fore his brief stay at Zio­pharm. Spero is de­vel­op­ing their lead can­di­date tebipen­em HBr, an oral car­bapen­em an­tibi­ot­ic, for those with com­pli­cat­ed uri­nary tract in­fec­tions and acute pyelonephri­tis.

Diego Ca­david

Diego Ca­david has signed on as CMO of Boston-based X4 Phar­ma­ceu­ti­cals af­ter the biotech nabbed fel­low Bio­gen alum Art Taveras as CSO last month. Ca­david heads over to X4 as the com­pa­ny press­es on­ward in their Phase III tri­al of ma­vorix­afor to treat those with WHIM syn­drome. Ca­david was pre­vi­ous­ly SVP and head of clin­i­cal de­vel­op­ment at Ful­crum Ther­a­peu­tics, which in Au­gust re­port­ed a Phase II dud in fa­cioscapu­lo­humer­al mus­cu­lar dy­s­tro­phy (FSHD) with its lead drug losmapi­mod. Try­ing to put an op­ti­mistic spin on it at the time, Ca­david said, “The ini­tial ob­ser­va­tion of greater re­duc­tion by losmapi­mod over place­bo in DUX4-dri­ven gene ex­pres­sion in the biop­sied mus­cles with the high­est base­line ex­pres­sion may rep­re­sent the po­ten­tial losmapi­mod has to treat the root cause of the dis­ease.”

Sanofi alum Howard Surks is join­ing Car­du­ri­on Phar­ma­ceu­ti­cals as the car­dio­vas­cu­lar dis­ease biotech’s CSO and head of trans­la­tion­al med­i­cine. This year Car­du­ri­on’s C-suite has seen some turnover with Pe­ter Lawrence tak­ing the helm as CEO and Chris Mora­bito tak­ing on the role of CMO. Surks was Sanofi’s head of trans­la­tion­al med­i­cine and clin­i­cal phar­ma­col­o­gy US, and be­fore his tenure at Sanofi, he was in­volved in trans­la­tion­al med­i­cine and car­dio­vas­cu­lar clin­i­cal de­vel­op­ment at fel­low phar­ma gi­ant Mer­ck.

John Maxwell

→ Feel­ing the ef­fects from the FDA’s re­buff of Liber­vant — an oral film for seizure con­trol — NJ-based Aque­s­tive Ther­a­peu­tics has re­vealed John Maxwell is step­ping down from his CFO post, ef­fec­tive at the end of the year. In his place will be in­ter­im CFO Ernie Toth, who had been CFO of EHE Health. Aque­s­tive in­tends to re­file an NDA de­spite re­ceiv­ing the CRL.

Kati­na Dor­ton

→ Pro­pelled by No­vo Ven­tures and Sanofi Ven­tures in a $55 mil­lion Se­ries B round in June, NL­RP3 in­flam­ma­some-fo­cused NodThera is flesh­ing out its C-suite with Don­ald Johns as CMO and Kati­na Dor­ton as CFO. Johns, a Bio­gen and No­var­tis vet, has moved on to Nodthera af­ter be­ing CMO and EVP of med­ical and sci­en­tif­ic af­fairs at Syn­tim­mune, bought out by Alex­ion in a $1.2 bil­lion deal. Dor­ton was just here this month when she se­cured a board ap­point­ment at Pan­dion Ther­a­peu­tics, and she was pre­vi­ous­ly the CFO at Re­pare Ther­a­peu­tics, Avro­bio and Im­mat­ics.

→ Sin­ga­pore-based cell ther­a­py biotech Tes­sa Ther­a­peu­tics is putting the fin­ish­ing touch­es on 2020 with an­oth­er change on the team, and this time it’s David McIn­tyre com­ing in as CFO. Tes­sa had cho­sen a new CEO (Jef­frey Buchal­ter) and new chair­man (Göran An­do) ear­li­er this year. McIn­tyre’s pre­vi­ous CFO stop was at Avi­ta Med­ical, and he’s al­so been a part­ner at Ap­ple Tree Part­ners.

Djord­je Fil­ipovic

→ Swiss au­toin­flam­ma­to­ry dis­ease biotech AB2 Bio has en­list­ed Djord­je Fil­ipovic as their chief com­mer­cial of­fi­cer. Fil­ipovic held nu­mer­ous lead­er­ship ti­tles at No­var­tis, start­ing at San­doz pre-merg­er in 1992 and serv­ing near­ly three decades, end­ing his run as the phar­ma gi­ant’s glob­al head of learn­ing, phar­ma. AB2 Bio is in a piv­otal Phase III tri­al with Tadekinig al­fa, and WuXi Bi­o­log­ics is col­lab­o­rat­ing with the biotech on man­u­fac­tur­ing the drug, a re­com­bi­nant IL-18 bind­ing pro­tein.

→ Rockville, MD-based CASI Phar­ma­ceu­ti­cals — which in-li­censed an an­ti-CD19 T cell ther­a­py from Chi­na’s Ju­ven­tas back in 2019 — has snagged Wei­hao Xu as CFO. Xu hails from Per­ma­nence Cap­i­tal, where he served as chief in­vest­ment of­fi­cer. Pri­or to that, he was CFO of Shang­hai-based dig­i­tal health­care com­pa­ny 111. In ad­di­tion, Xu for­mer­ly held roles at Matthews In­ter­na­tion­al Cap­i­tal Man­age­ment, Permal As­set Man­age­ment and Lans­downe Part­ners.

Ter­ri Gaskell

→ UK-based Rin­ri Ther­a­peu­tics, fo­cused on hear­ing restora­tion via cell-based ther­a­pies and spun out of the Uni­ver­si­ty of Sheffield, has se­lect­ed Ter­ri Gaskell as chief tech­nol­o­gy of­fi­cer. Gaskell takes the CTO job af­ter a 7-year run at the Cell and Gene Ther­a­py Cat­a­pult, where she was most re­cent­ly their head of pro­gram de­liv­ery.

→ Re­brand­ing from its pre­vi­ous name An­a­lyt­ics 4 Life, Toron­to-based CorVista Health has locked in Scott Burg­er as chief com­mer­cial of­fi­cer and VP. Burg­er has Big Phar­ma ex­pe­ri­ence as a di­rec­tor in J&J’s car­dio­vas­cu­lar group pri­or to his new po­si­tion at CorVista Health, which us­es a car­diac di­ag­nos­tic plat­form called the CorVista Sys­tem for heart dis­ease di­ag­noses.

Chris Kurtz

→ With its an­ti­fun­gal can­di­date reza­fun­gin in Phase III, San Diego biotech Cidara Ther­a­peu­tics has poached Chris Kurtz from Gilead to be their EVP of tech­ni­cal op­er­a­tions. Kurtz led com­mer­cial API man­u­fac­tur­ing at the phar­ma gi­ant with such drugs as Vek­lury (known more com­mon­ly as remde­sivir in the age of Covid-19) and Bik­tarvy. Be­fore Gilead, Kurtz was VP for drug de­vice in­dus­tri­al­iza­tion at Ab­b­Vie and an ex­ec at Alexza Phar­ma­ceu­ti­cals and No­vo Nordisk.

→ Bei­jing gene edit­ing play­er Edi­Gene, which net­ted $67 mil­lion in an Oc­to­ber Se­ries B, has made two new ap­point­ments with Bo Zhang (head of US sub­sidiary) and Ke­hua Fan (head of busi­ness de­vel­op­ment). Zhang, a vet­er­an of Mer­ri­mack Phar­ma­ceu­ti­cals and Cobalt Bio­med­i­cine, was VP at Klus Phar­ma pri­or to his Edi­Gene ar­rival. And Fan, who has Big Phar­ma stints at GSK, Sanofi and Pfiz­er un­der her belt, leaves her po­si­tion at Jun­shi Bio­sciences as head of strat­e­gy and part­ner­ship.

Erik Rut­jens

→ UK-based Enara Bio, re­brand­ed in June from its orig­i­nal name Er­vaxx and try­ing to break through in off-the-shelf CAR-T and can­cer vac­cines with their TCR dis­cov­ery and “Dark Anti­gen” plat­forms, has in­stalled Erik Rut­jens as VP, cell ther­a­py op­er­a­tions. Rut­jens comes to Enara Bio af­ter hold­ing a se­ries of ti­tles at No­var­tis, cul­mi­nat­ing in his time as head of en­abling tech­nolo­gies & process en­gi­neer­ing. Enara Bio has al­so ap­point­ed two new mem­bers of their sci­en­tif­ic ad­vi­so­ry board with Vor Bio­phar­ma CTO Sadik Kas­sim and Michael Quigley, Gilead’s SVP, re­search bi­ol­o­gy.

→ Wa­ter­town, MA pro­tein degra­da­tion play­er Kymera Ther­a­peu­tics, one of a mul­ti­tude of biotechs to go pub­lic in 2020 by scor­ing an up­sized $173.7 mil­lion IPO, has wel­comed two new ex­ecs with William Leong as VP of CMC and Paul Cox as VP of in­vestor re­la­tions and com­mu­ni­ca­tions. Leong, a Cel­gene and Scher­ing-Plough vet, makes the move to Kymera from his gig at Com­plexa as VP, tech­ni­cal op­er­a­tions. Cox has pre­vi­ous­ly been in in­vestor re­la­tions at Sage Ther­a­peu­tics, Neon Ther­a­peu­tics and Voy­ager Ther­a­peu­tics.

Badred­din Edris

Spring­Works Ther­a­peu­tics — which swapped an ex-Pfiz­er drug out with Jazz Phar­ma­ceu­ti­cals for $35 mil­lion back in Oc­to­ber — has an­nounced two pro­mo­tions. Cur­rent CBO Badred­din Edris has moved up to the po­si­tion of COO, while L Mary Smith, cur­rent SVP of clin­i­cal re­search and de­vel­op­ment, has been pro­mot­ed to chief de­vel­op­ment of­fi­cer. Edris joined the com­pa­ny back in 2018 and pre­vi­ous­ly held roles at two Or­biMed port­fo­lio com­pa­nies: CBO at Sil­ver­back Ther­a­peu­tics and COO at Edge­wise Ther­a­peu­tics. Smith has been with the com­pa­ny since its in­cep­tion in 2017 and for­mer­ly served as EVP of gene ther­a­py at Pfiz­er sub­sidiary Bam­boo Ther­a­peu­tics and as VP of prod­uct de­vel­op­ment at Unit­ed Ther­a­peu­tics.

→ Af­ter quite the ug­ly bat­tle, Zio­pharm‘s saga with Wa­ter­Mill has fi­nal­ly drawn to a close. Zio­pharm has made the ad­di­tions of Jaime Vieser and Hol­ger Weis to its board of di­rec­tors, with chair­man Scott Tar­riff hit­ting the ex­it. It’s not clear if Wa­ter­Mill will push for the last in­di­vid­ual to step down and be re­placed with Wa­ter­Mill founder Robert Post­ma. Weis was the for­mer pres­i­dent of De­meRx while Vieser is co-founder and chief in­vest­ment of­fi­cer of Cas­tle Hill As­set Man­age­ment.

Jen­nifer Hon­ey­cutt

Jen­nifer Hon­ey­cutt start­ed at Dana­her 21 years ago af­ter the Hach ac­qui­si­tion. Now she’ll take on a new role as EVP, ef­fec­tive Jan 1. Hon­ey­cutt had been VP and group ex­ec­u­tive over­see­ing three en­ti­ties: Pall (which Dana­her pur­chased in 2015, earn­ing her the ti­tle of pres­i­dent of Pall), IDT and Dana­her’s Life Sci­ences plat­form in Chi­na.

Karyopharm Ther­a­peu­tics — which won an FDA OK last year for its mul­ti­ple myelo­ma drug de­spite fevered ob­jec­tions — has pulled in Michael Mano as SVP, gen­er­al coun­sel. Mano joins the com­pa­ny af­ter a stint as coun­sel, busi­ness de­vel­op­ment at Bio­gen.

Lin­da Holm­ström

→ Stock­holm phar­ma On­copep­tides, now helmed by ex-Toca­gen CEO Mar­ty Du­vall, has wel­comed Lin­da Holm­ström as di­rec­tor of in­vestor re­la­tions. Holm­ström, who worked in com­mu­ni­ca­tions at Re­ci­pharm, joins hema­to­log­i­cal dis­ease-fo­cused On­copep­tides af­ter four years as se­nior cor­po­rate com­mu­ni­ca­tions and in­vestor re­la­tions man­ag­er for So­bi.

→ UK-based Touch­light — fo­cused on the de­vel­op­ment of DNA-based ge­net­ic med­i­cines — has tapped Satish Muchakay­ala as di­rec­tor of reg­u­la­to­ry af­fairs. Muchakay­ala brings to the ta­ble ex­pe­ri­ence from his time at UCB, J&J and GSK. In ad­di­tion, the com­pa­ny has brought on John Dwyer, for­mer part­ner at PwC UK, to its board of di­rec­tors as non-ex­ec­u­tive di­rec­tor.

Camille Bedrosian

→ Boston-based Rhythm Phar­ma­ceu­ti­cals, led by David Meek­er and weeks re­moved from get­ting the FDA seal of ap­proval on set­melan­otide for rare ge­net­ic dis­or­ders of obe­si­ty, has hit two new notes on the board of di­rec­tors with Camille Bedrosian and Lynn Tetrault. Bedrosian has been CMO at Ul­tragenyx since 2018, and Tetrault was in cor­po­rate af­fairs at As­traZeneca from 1993-2014.

→ Dutch macro­mol­e­cule biotech Sapreme has tapped Björn Cochlovius to be chair­man of the board. Cochlovius, who al­so chairs the board at Iso­geni­ca, has worked in busi­ness de­vel­op­ment for Ab­b­Vie and Roche.

Kel­ly Ro­mano

Rais­ing $204 mil­lion in an up­sized IPO this fall and tar­get­ing Alzheimer’s and Parkin­son’s, Leen Kawas-helmed Athi­ra Phar­ma out of Seat­tle has added Kel­ly Ro­mano to their board of di­rec­tors. Ro­mano is the founder and CEO of BlueRip­ple Cap­i­tal and spent more than three decades at Unit­ed Tech­nolo­gies Corp.

→ Neu­ro­bi­ol­o­gy play­er XW­Phar­ma has reeled in Michael Mor­ris­sey to its board of di­rec­tors. Mor­ris­sey is the cur­rent di­rec­tor, pres­i­dent and CEO of Ex­elix­is.

→ Just af­ter they hired Steve Harbin as COO and chief of staff, Cam­bridge, MA vi­ral im­munother­a­py out­fit On­corus has made Scott Canute a mem­ber of the board of di­rec­tors. Canute, the for­mer man­u­fac­tur­ing ex­ec at Eli Lil­ly and Gen­zyme, is al­so on the board at Flex­ion Ther­a­peu­tics.

Al­bert Cha

As­cendis Phar­ma A/S SVP and chief le­gal of­fi­cer Michael Wolf Jensen won’t put him­self up for re-elec­tion to the board of di­rec­tors, while Al­bert Cha has re­placed him at the Copen­hagen-based com­pa­ny as chair­man. Cha, a Vi­vo Cap­i­tal vet and board mem­ber for the last six years, is al­so on the board KalVista Phar­ma­ceu­ti­cals. Jensen had been chair­man since 2008.

Sandip Ka­pa­dia has been ap­point­ed to the board of di­rec­tors at Lu­ca Santarel­li start­up Vec­tivBio. Ka­pa­dia, the CFO at In­ter­cept, held sev­er­al po­si­tions at No­var­tis, in­clud­ing CFO of San­doz in North Amer­i­ca.

An­drea Hes­lin Smi­ley

→ Set­tling in with a new CEO af­ter the Robert Chioi­ni dra­ma, Rock­well Med­ical has brought in Eli Lil­ly vet An­drea Hes­lin Smi­ley as a board mem­ber. Smi­ley has been pres­i­dent and CEO at VMS Bio­Mar­ket­ing for nine years.

Spec­trum Phar­ma­ceu­ti­cals — which saw its shares crater last De­cem­ber — has re­cruit­ed No­ra Bren­nan to its board of di­rec­tors. Bren­nan cur­rent­ly serves as CFO of TELA Bio and has pre­vi­ous­ly served as CFO at Xeris Phar­ma­ceu­ti­cals.

Jef­frey Vacir­ca

→ Be­yond­Spring, a can­cer-fo­cused biotech with deep roots in Chi­na, has named Jef­frey Vacir­ca a mem­ber of its board of di­rec­tors. Vacir­ca comes from New York Can­cer & Blood Spe­cial­ists, where he serves as CEO and chair­man. In ad­di­tion, he sits on the boards of OneOn­col­o­gy, the Amer­i­can Red Cross of Greater New York, New York Can­cer Foun­da­tion, Odonate Ther­a­peu­tics and Spec­trum Phar­ma­ceu­ti­cals.

SAB Bio­ther­a­peu­tics has ap­point­ed Mani Mo­hin­dru and Mer­ck vet Mervyn Turn­er to its board of di­rec­tors. Mo­hin­dru was the for­mer CFO of CereX­is and was CFO and chief strat­e­gy of­fi­cer at Cara Ther­a­peu­tics. Mean­while, Turn­er cur­rent­ly op­er­ates his own con­sult­ing firm, MJ Turn­er Con­sult­ing.

Michel Thérin

→ Medtech Tis­si­um has pulled in Michel Thérin to its board of di­rec­tors. Cur­rent­ly, Thérin is pres­i­dent of ad­vanced ther­a­pies at Siemens Health­i­neers. Pri­or to that, he spent more than a decade at Medtron­ic.

→ Man­u­fac­tur­ing tech com­pa­ny Ori Biotech has reeled in Mor­rie Ruf­fin, Jian Irish and Dean­na Pe­tersen to its ad­vi­so­ry board. In ad­di­tion, the com­pa­ny has made sev­er­al new ap­point­ments with the hir­ing of David Smith as VP of tech­ni­cal op­er­a­tions; Shaun Mans­field as sci­en­tist; and Amisha Pa­tel as qual­i­ty man­ag­er.

→ Is­rael-based MeMed has wel­comed Chris Hi­b­berd to its board of di­rec­tors. Cur­rent­ly, Hi­b­berd serves as CEO and ex­ec­u­tive chair­man of Nu­cle­ix.

How Pa­tients with Epilep­sy Ben­e­fit from Re­al-World Da­ta

Amanda Shields, Principal Data Scientist, Scientific Data Steward

Keith Wenzel, Senior Business Operations Director

Andy Wilson, Scientific Lead

Real-world data (RWD) has the potential to transform the drug development industry’s efforts to predict and treat seizures for patients with epilepsy. Anticipating or controlling an impending seizure can significantly increase quality of life for patients with epilepsy. However, because RWD is secondary data originally collected for other purposes, the challenge is selecting, harmonizing, and analyzing the data from multiple sources in a way that helps support patients.

$DNA is once again on NYSE; FDA clears Soliris chal­lenger for the mar­ket; Flag­ship’s think­ing big again with eR­NA; and more

Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add Endpoints Weekly. New to Endpoints? Sign up here.

I still remember the uncertainty in the air last year when nobody was sure whether ASCO would cancel their in-person meeting. But it’s now back again for the second virtual conference, and Endpoints News is here for it. Check out our 2-day event reviewing the landscape of cancer R&D and send news our way.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 105,400+ biopharma pros reading Endpoints daily — and it's free.

Gene ther­a­py from Bio­gen's $800M buy­out flops in mid-stage study, deal­ing blow to new am­bi­tions

The #2 candidate from Biogen’s $800 million ocular gene therapy buyout has failed in a mid-stage trial, dealing an early blow to the big biotech’s plans to revitalize its pipeline with new technologies.

Biogen announced that the candidate, an experimental treatment for a rare and progressive form of blindness called X-linked retinitis pigmentosa (XLRP), failed to sufficiently improve vision in patients’ treated eye — patients only received an injection in one eye — after a year, on a standard scale, compared to their untreated eye. The company said they saw “positive trends” on several secondary endpoints, including visual acuity, but declined to say whether the trial actually hit any of those endpoints.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 105,400+ biopharma pros reading Endpoints daily — and it's free.

Vas Narasimhan (Photographer: Simon Dawson/Bloomberg via Getty Images)

No­var­tis whiffs on En­tresto study af­ter heart at­tacks — but that does­n't mean it's go­ing down qui­et­ly

If Novartis learned one thing from its interaction with the FDA over its latest heart failure approval for Entresto, it was that missing a primary endpoint may not be the nail in the coffin. Now, Entresto has missed again on a late-stage study in high-risk heart patients, and it’s already sowing the seeds for a path forward regardless.

Novartis’ Entresto couldn’t best standard-of-care ramipril in staving off a composite of deaths and heart failure events in patients with left ventricular systolic dysfunction and/or pulmonary congestion who have had a prior heart attack, according to topline data from the Phase III PARADISE-MI study revealed Saturday at the virtual American College of Cardiology meeting.

Michael Dell (Richard Drew, AP Images)

'Dude, you're get­ting a Del­l' — as a new deep-pock­et biotech in­vestor

What happens when you marry longtime insiders in the global biotech VC game with the family fund of tech billionaire Michael Dell, a synthetic biology legend out of MIT and Harvard and the former director of the NCI?

Today, the answer is a newly financed, $200 million biotech SPAC now cruising the industry for a top player interested in finding a short cut to Nasdaq.

Orion Biotech Opportunities priced their blank check company today, raising $200 million with Dell’s multibillion-dollar MSD group’s commitment on investing another $20 million in a forward-purchase agreement.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

BAR­DA slows its $9B en­gine for new Covid-19 ther­a­peu­tics

The Biomedical Advanced Research and Development Authority is cooling its jets in looking for new, potential Covid-19 treatments, at least in the near term.

An HHS spokesperson told Endpoints News via email, “to date, BARDA has obligated more than $9 billion for the development and/or purchase of 13 therapeutics, beginning in February 2020 with support to develop Regeneron’s monoclonal antibody therapeutic. Therapeutics are an important element of the COVID-19 response, and we are focused on the programs currently underway and/or in negotiation using the funds available to us.”

As Co­di­ak en­ters 'next phase of growth,' Jen­nifer Whel­er steps in­to CMO role; Mark Tim­ney lines up his sec­ond CEO op­por­tu­ni­ty af­ter Pur­due Phar­ma reign

Most CMOs don’t start out as art students. But after getting her bachelor’s in art history from Princeton University, Jennifer Wheler decided to go after an MD from Cornell, kicking off a decades-long career in biopharma. Her next move? Leading the team at Codiak BioSciences to deliver therapeutics using a form of cellular postal service called exosomes.

“I was captivated by the science and the potential for exosomes to have transformational impact in cancer and other disease areas,” the incoming CMO told Endpoints News via email. “Codiak has a potent combination of great science and wonderfully experienced and kind people — it doesn’t get much better.”

Bris­tol My­ers backs up its case for heart drug mava­camten as FDA weighs app in car­diomy­opa­thy

When Bristol Myers Squibb signed off on its $13 billion acquisition of MyoKardia back in October, it was making a big bet that lead drug mavacamten could prove a game changer in cardiac myopathy. Now, with the drug up for FDA review, Bristol Myers is backing up its case with new quality of life data.

Patients dosed with myosin inhibitor mavacamten posted a clinically significant increase in scores on the Kansas City Cardiomyopathy Questionnaire, a catch-all summary of symptoms and quality of life markers, over placebo at 30 weeks, according to data from the Phase III EXPLORER-HCM study presented Saturday at the virtual American College of Cardiology meeting.

UP­DAT­ED: Apel­lis bags FDA nod for Soliris chal­lenger with a dif­fer­ent path­way to PNH — but can it slay the gi­ant?

With a blockbuster rare disease giant in its sights in Alexion’s Soliris, small biotech Apellis has reason to think its competitor is worthy of the spotlight. Now, with the FDA on its side, Apellis will get its chance to be the David to Alexion’s Goliath.

The FDA on Friday approved Empaveli (pegcetacoplan), a C3 complement inhibitor the biotech thinks can prove a worthy challenger to Alexion’s C5 inhibitors Soliris and follow-up drug Ultomiris in rare disease paroxysmal nocturnal hemoglobinuria (PNH).